Safety of Biologics Therapy Monoclonal Antibodies, Cytokines, Fusion
This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety o
- PDF / 12,775,614 Bytes
- 623 Pages / 439.43 x 683.15 pts Page_size
- 60 Downloads / 150 Views
Safety of Biologics Therapy Monoclonal Antibodies, Cytokines, Fusion Proteins, Hormones, Enzymes, Coagulation Proteins, Vaccines, Botulinum Toxins
123
Safety of Biologics Therapy
Brian A. Baldo
Safety of Biologics Therapy Monoclonal Antibodies, Cytokines, Fusion Proteins, Hormones, Enzymes, Coagulation Proteins, Vaccines, Botulinum Toxins
Brian A. Baldo (Retired) AUA(Pharmacy); BSc(Hons); PhD Formerly: Royal North Shore Hospital of Sydney Head, Molecular Immunology Unit Kolling Institute of Medical Research and University of Sydney Sydney, NSW, Australia
ISBN 978-3-319-30470-0 ISBN 978-3-319-30472-4 DOI 10.1007/978-3-319-30472-4
(eBook)
Library of Congress Control Number: 2016943849 © Springer International Publishing Switzerland 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG Switzerland
Dedicated to the memories of my mother and father and to Gail MacDiarmid for the cherished years of support, partnership, and mutual devotion
Preface
In writing this book, the author’s primary intention was to produce an up-to-date text book on approved biologic therapies as far as that is possible in this time of rapidly evolving and seemingly ever-expanding developments in biotherapeutic research and the introduction of new and novel biopharmaceuticals. Emergence of the disciplines of genomics and proteomics, together with molecular biological approaches to elucidate the functions of single genes, continues to reveal the complexities and multifaceted nature of diseases such as cancer, autoimmunity, and metabolic disorders and to identify potential targets for the development of new drug therapies. Targeted approaches, long practiced in relation to peptide hormones and enzymes, now so often drive the extraordinary interest in, and development of, monoclonal antibody, fusion protein, and cytokine therapies. Added stimulus has been
Data Loading...
